File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1111/hpb.12324
- Scopus: eid_2-s2.0-84922677993
- PMID: 25284590
- WOS: WOS:000349697600006
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Radiofrequency ablation versus transarterial chemoembolization for unresectable solitary hepatocellular carcinomas sized 5-8 cm
Title | Radiofrequency ablation versus transarterial chemoembolization for unresectable solitary hepatocellular carcinomas sized 5-8 cm |
---|---|
Authors | |
Issue Date | 2015 |
Publisher | Wiley-Blackwell Publishing Ltd. The Journal's web site is located at http://www.wiley.com/WileyCDA/WileyTitle/productCd-HPB.html |
Citation | HPB, 2015, v. 17 n. 3, p. 226-231 How to Cite? |
Abstract | OBJECTIVES:
This retrospective review was conducted to compare the efficacy of radiofrequency ablation (RFA) with that of transarterial chemoembolization (TACE) in treating large (5-8 cm) unresectable solitary hepatocellular carcinomas (HCCs).
METHODS:
Patients with large unresectable solitary HCCs primarily treated by RFA or TACE were reviewed. The primary endpoint was overall survival. Secondary endpoints were tumour response, time to disease progression, and treatment-related morbidity and mortality.
RESULTS:
There were 15 patients in the RFA group. Of these, 12 achieved complete ablation, one had ablation site recurrence, and five developed complications. Median disease-free survival in this group was 13.0 months (range: 2.8-38.0 months). The TACE group included 26 patients, of whom four obtained a partial response, none achieved a complete response, and five developed complications. The median time to disease progression in this group was 8.0 months (range: 1.0-68.0 months). There were no hospital deaths in this series. Median survival was 39.8 months in the RFA group and 19.8 months in the TACE group (P = 0.257). Rates of 1-, 2- and 5-year survival were 93.3%, 86.2% and 20.9%, respectively, in the RFA group and 73.1%, 40.6% and 18.3%, respectively, in the TACE group.
CONCLUSIONS:
Both RFA and TACE are feasible treatments for large unresectable solitary HCCs. Both modes show comparable rates of complications and longterm survival, but RFA achieves better initial tumour control and results in better short-term survival.
© 2014 International Hepato-Pancreato-Biliary Association. |
Description | This study was presented at the 11th World Congress of the IHPBA, 22–27 March 2014, Seoul as 'Outcomes of unresectable solitary hepatocellular carcinomas China sized 5 to 8cm treated by radiofrequency ablation versus transarterial chemoembolization' by WC Dai. |
Persistent Identifier | http://hdl.handle.net/10722/207317 |
ISSN | 2023 Impact Factor: 2.7 2023 SCImago Journal Rankings: 1.141 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Dai, WC | - |
dc.contributor.author | Cheung, TT | - |
dc.contributor.author | Chok, KSH | - |
dc.contributor.author | Chan, ACY | - |
dc.contributor.author | Sharr, WW | - |
dc.contributor.author | Tsang, SHY | - |
dc.contributor.author | Yuen, WK | - |
dc.contributor.author | Chan, SC | - |
dc.contributor.author | Fan, ST | - |
dc.contributor.author | Lo, CM | - |
dc.contributor.author | Poon, RTP | - |
dc.date.accessioned | 2014-12-19T10:20:51Z | - |
dc.date.available | 2014-12-19T10:20:51Z | - |
dc.date.issued | 2015 | - |
dc.identifier.citation | HPB, 2015, v. 17 n. 3, p. 226-231 | - |
dc.identifier.issn | 1365-182X | - |
dc.identifier.uri | http://hdl.handle.net/10722/207317 | - |
dc.description | This study was presented at the 11th World Congress of the IHPBA, 22–27 March 2014, Seoul as 'Outcomes of unresectable solitary hepatocellular carcinomas China sized 5 to 8cm treated by radiofrequency ablation versus transarterial chemoembolization' by WC Dai. | - |
dc.description.abstract | OBJECTIVES: This retrospective review was conducted to compare the efficacy of radiofrequency ablation (RFA) with that of transarterial chemoembolization (TACE) in treating large (5-8 cm) unresectable solitary hepatocellular carcinomas (HCCs). METHODS: Patients with large unresectable solitary HCCs primarily treated by RFA or TACE were reviewed. The primary endpoint was overall survival. Secondary endpoints were tumour response, time to disease progression, and treatment-related morbidity and mortality. RESULTS: There were 15 patients in the RFA group. Of these, 12 achieved complete ablation, one had ablation site recurrence, and five developed complications. Median disease-free survival in this group was 13.0 months (range: 2.8-38.0 months). The TACE group included 26 patients, of whom four obtained a partial response, none achieved a complete response, and five developed complications. The median time to disease progression in this group was 8.0 months (range: 1.0-68.0 months). There were no hospital deaths in this series. Median survival was 39.8 months in the RFA group and 19.8 months in the TACE group (P = 0.257). Rates of 1-, 2- and 5-year survival were 93.3%, 86.2% and 20.9%, respectively, in the RFA group and 73.1%, 40.6% and 18.3%, respectively, in the TACE group. CONCLUSIONS: Both RFA and TACE are feasible treatments for large unresectable solitary HCCs. Both modes show comparable rates of complications and longterm survival, but RFA achieves better initial tumour control and results in better short-term survival. © 2014 International Hepato-Pancreato-Biliary Association. | - |
dc.language | eng | - |
dc.publisher | Wiley-Blackwell Publishing Ltd. The Journal's web site is located at http://www.wiley.com/WileyCDA/WileyTitle/productCd-HPB.html | - |
dc.relation.ispartof | HPB | - |
dc.title | Radiofrequency ablation versus transarterial chemoembolization for unresectable solitary hepatocellular carcinomas sized 5-8 cm | - |
dc.type | Article | - |
dc.identifier.email | Dai, WC: daiwc@hku.hk | - |
dc.identifier.email | Cheung, TT: cheung68@hku.hk | - |
dc.identifier.email | Chok, KSH: chok6275@hku.hk | - |
dc.identifier.email | Chan, ACY: acchan@hku.hk | - |
dc.identifier.email | Sharr, WW: wwsharr@hku.hk | - |
dc.identifier.email | Yuen, WK: drwkyuen@hku.hk | - |
dc.identifier.email | Chan, SC: chanlsc@hkucc.hku.hk | - |
dc.identifier.email | Fan, ST: stfan@hku.hk | - |
dc.identifier.email | Lo, CM: chungmlo@hkucc.hku.hk | - |
dc.identifier.email | Poon, RTP: poontp@hku.hk | - |
dc.identifier.authority | Chan, ACY=rp00310 | en_US |
dc.identifier.authority | Chan, SC=rp01568 | en_US |
dc.identifier.authority | Fan, ST=rp00355 | en_US |
dc.identifier.authority | Lo, CM=rp00412 | en_US |
dc.identifier.authority | Poon, RTP=rp00446 | en_US |
dc.description.nature | link_to_OA_fulltext | - |
dc.identifier.doi | 10.1111/hpb.12324 | - |
dc.identifier.pmid | 25284590 | - |
dc.identifier.pmcid | PMC4333783 | - |
dc.identifier.scopus | eid_2-s2.0-84922677993 | - |
dc.identifier.hkuros | 241972 | - |
dc.identifier.volume | 17 | - |
dc.identifier.issue | 3 | - |
dc.identifier.spage | 226 | - |
dc.identifier.epage | 231 | - |
dc.identifier.isi | WOS:000349697600006 | - |
dc.publisher.place | United Kingdom | - |
dc.identifier.issnl | 1365-182X | - |